<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">39419167</PMID><DateRevised><Year>2024</Year><Month>10</Month><Day>17</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1878-3511</ISSN><JournalIssue CitedMedium="Internet"><PubDate><Year>2024</Year><Month>Oct</Month><Day>15</Day></PubDate></JournalIssue><Title>International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases</Title><ISOAbbreviation>Int J Infect Dis</ISOAbbreviation></Journal><ArticleTitle>Temporal trajectories of long-COVID symptoms in adults with 22 months follow-up in a prospective cohort study in Norway.</ArticleTitle><Pagination><StartPage>107263</StartPage><MedlinePgn>107263</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.ijid.2024.107263</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S1201-9712(24)00334-5</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">There is a lack of large studies on long-COVID symptoms with symptoms measurements before the onset of COVID-19. Therefore, long-COVID is still poorly defined.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">The Norwegian COVID-19 Cohort Study is a population-based, open cohort of adult participants (aged 18-96 years) from Norway. From March 27, 2020, participants were recruited through social media, invitations, and nationwide media coverage. Fourteen somatic and cognitive symptoms were assessed at baseline and four follow-ups for up to 22 months. SARS-CoV-2 test status was obtained from a mandatory national registry or from self-report.</AbstractText><AbstractText Label="FINDINGS" NlmCategory="RESULTS">After follow-up, 15 737 participants had a SARS-CoV-2-positive test, 67 305 a negative test, and 37 563 were still untested. Persistent symptoms reported more frequently by positive compared with negative participants one month after infection, were memory problems (3-6 months: adjusted odds ratio (aOR)&#x202f;=&#x202f;6.8, CI&#x202f;=&#x202f;5.7-8.1; &gt;18 months: aOR&#x202f;=&#x202f;9.4, CI&#x202f;=&#x202f;4.1-22), and concentration problems (3-6 months: aOR&#x202f;=&#x202f;4.1, CI&#x202f;=&#x202f;3.5-4.7; &gt;18 months: aOR&#x202f;=&#x202f;4.4, CI&#x202f;=&#x202f;2.0-9.7) as well fatigue, dyspnoea, anosmia and dysgeusia.</AbstractText><AbstractText Label="INTERPRETATION" NlmCategory="CONCLUSIONS">COVID-19 was associated with cognitive symptoms, anosmia, dysgeusia, dyspnoea and fatigue as well as worsening of overall health up to 22 months after a SARS-CoV-2 test, even when correcting for symptoms before the onset of COVID-19.</AbstractText><CopyrightInformation>Copyright &#xa9; 2024. Published by Elsevier Ltd.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Ellingjord-Dale</LastName><ForeName>Merete</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Oslo University Hospital, Department of Microbiology, PO Box 4950 Nydalen, Oslo, Norway. Electronic address: mellingjord@hotmail.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nygaard</LastName><ForeName>Anders Benteson</ForeName><Initials>AB</Initials><AffiliationInfo><Affiliation>Oslo University Hospital, Department of Microbiology, PO Box 4950 Nydalen, Oslo, Norway.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>St&#xf8;er</LastName><ForeName>Nathalie C</ForeName><Initials>NC</Initials><AffiliationInfo><Affiliation>Cancer Registry of Norway, Research Department, 0379 Oslo, Norway.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>B&#xf8;</LastName><ForeName>Ragnhild</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>University of Oslo, Department of Psychology, 0373 Oslo, Norway.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Landr&#xf8;</LastName><ForeName>Nils Inge</ForeName><Initials>NI</Initials><AffiliationInfo><Affiliation>University of Oslo, Department of Psychology, 0373 Oslo, Norway.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Brunvoll</LastName><ForeName>Sonja Hjellegjerde</ForeName><Initials>SH</Initials><AffiliationInfo><Affiliation>Oslo University Hospital, Department of Microbiology, PO Box 4950 Nydalen, Oslo, Norway.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Istre</LastName><ForeName>Mette</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Oslo University Hospital, Department of Microbiology, PO Box 4950 Nydalen, Oslo, Norway.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kalleberg</LastName><ForeName>Karl Trygve</ForeName><Initials>KT</Initials><AffiliationInfo><Affiliation>Age Labs AS, 0373 Oslo, Norway.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dahl</LastName><ForeName>John Arne</ForeName><Initials>JA</Initials><AffiliationInfo><Affiliation>Oslo University Hospital, Department of Microbiology, PO Box 4950 Nydalen, Oslo, Norway.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Geng</LastName><ForeName>Linda</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Medicine, Stanford University School of Medicine, Stanford, CA 94305, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tsilidis</LastName><ForeName>Kostas</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Imperial College London, School of Public Health, Department of Epidemiology and Biostatistics, London SW7 2AZ, UK; University of Ioannina School of Medicine, Department of Hygiene and Epidemiology, Ioannina, Greece.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Riboli</LastName><ForeName>Elio</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Imperial College London, School of Public Health, Department of Epidemiology and Biostatistics, London SW7 2AZ, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ursin</LastName><ForeName>Giske</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Cancer Registry of Norway, Oslo, Norway; University of Oslo, Institute of Basic Medical Sciences, Department of Nutrition, 0373 Oslo, Norway; University of Southern California, Department of Preventive Medicine, Los Angeles, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>S&#xf8;raas</LastName><ForeName>Arne</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Microbiology, Oslo University Hospital, PO Box 4950 Nydalen, 0424 Oslo, Norway.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>10</Month><Day>15</Day></ArticleDate></Article><MedlineJournalInfo><Country>Canada</Country><MedlineTA>Int J Infect Dis</MedlineTA><NlmUniqueID>9610933</NlmUniqueID><ISSNLinking>1201-9712</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Long-COVID</Keyword><Keyword MajorTopicYN="N">post-COVID symptoms</Keyword><Keyword MajorTopicYN="N">pre-COVID symptoms</Keyword><Keyword MajorTopicYN="N">prospective cohort study</Keyword></KeywordList><CoiStatement>Declaration of competing interest The authors of the manuscript &#x201c;Temporal trajectories of COVID-19 symptoms in adults with 22 months follow-up in a prospective cohort study in Norway&#x201d; have no conflict of interest to disclose.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>8</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2024</Year><Month>9</Month><Day>29</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>10</Month><Day>5</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>10</Month><Day>18</Day><Hour>7</Hour><Minute>19</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>10</Month><Day>18</Day><Hour>7</Hour><Minute>19</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>10</Month><Day>17</Day><Hour>19</Hour><Minute>13</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39419167</ArticleId><ArticleId IdType="doi">10.1016/j.ijid.2024.107263</ArticleId><ArticleId IdType="pii">S1201-9712(24)00334-5</ArticleId></ArticleIdList></PubmedData></PubmedArticle></PubmedArticleSet>